Philip O. Renzullo
$1,438,731
Fred Hutchinson Cancer Center
Washington
National Institute of Allergy and Infectious Diseases (NIAID)
On-going US government sponsored COVID-19 vaccine trials require screening, enrolling, and following over 150,000 volunteer study participants over 24-36 months. The trial participants are selected based on their risk of COVID-19 infection, with trial participants coming from settings with high rates of community transmission, groups with higher risk of progression to symptomatic disease, or both. Study staff working on COVID-19 vaccine trials interact with trial participants during scheduled trial assessments and unscheduled sick visits, which includes high risk procedures such as nasal swabbing and performing physical examinations in often poorly ventilated environments. As a result, a regular supply of personal protective equipment (PPE), including surgical masks, face shields or goggles, gowns, and disposable gloves, is critical for their own protection and for prevention of transmission within the clinic. This project will provide on-going PPE support to COVID-19 Prevention Network (CoVPN) trials across three continents, completing work anticipated through 2023. 1